reports
Net Asset Value(s)
Net Asset Value(s) Octopus AIM VCT plc Net Asset Value Octopus AIM VCT plc announces that as at 22 April 2024 the unaudited net asset value of the Ordinary shares was approximately 63.8 pence per share. For further information, please contact: Rachel PeatOctopus Company Secretarial Services LimitedTel: +44 (0)80 0316 2067 LEI: 213800C5JHJUQLAFP619 ...
Net Asset Value(s)
Net Asset Value(s) Octopus AIM VCT 2 plc Net Asset Value Octopus AIM VCT 2 plc announces that as at 22 April 2024 the unaudited net asset value of the Ordinary shares was approximately 49.2 pence per share. For further information, please contact: Rachel PeatOctopus Company Secretarial Services LimitedTel: +44 (0)80 0316 2067 LEI: 213800BW27BKJCI35L17 ...
EQS-News: CureVac Announces Financial Results for the Fourth Quarter a...
Issuer: CureVac / Key word(s): Annual Results CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update 24.04.2024 / 13:06 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Fede...
EQS-News: CureVac veröffentlicht Finanzergebnisse für das vierte Quart...
Emittent / Herausgeber: CureVac / Schlagwort(e): Jahresergebnis CureVac veröffentlicht Finanzergebnisse für das vierte Quartal sowie das Gesamtjahr 2023 und informiert über seine Geschäftsentwicklung 24.04.2024 / 13:06 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac veröffentlicht Finanzergebnisse für das vierte Quartal sowie das Gesamtjahr 2023 und informiert über seine Geschäftsentwicklung Organisatorische Umgestaltung und Verschlankung des Unternehmens soll Strukturen optimieren, Effizienz steigern und Betriebskosten s...
Form 8.3 - UK Commercial Property REIT
Form 8.3 - UK Commercial Property REIT 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this f...
Zhongyu Gas Holdings: 1 director
A director at Zhongyu Gas Holdings bought 500,000 shares at 4.900HKD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
- Chris Hoare
SingTel (Buy, TP: S$ 4.4, +83%) SingTel’s market cap now fully covere...
With Bharti in sight of US$100bn market cap and SingTel languishing after the abortive sale of a stake in Optus, SingTel’s stake in Bharti is now worth the same as SingTel’s entire market cap. This also means that SingTel’s SOP discount is at all-time highs of 50%. In this note we look at how management could address this through buybacks, and what the accretion impact of selling stakes in Bharti to buy back SingTel shares would be.
- Taras Kotovych
Bond Market Insight -- Bond market waits for NBU to cut rates
Yesterday's auction received UAH9.4bn of demand, mainly for 12-month bills, but also strong demand for two- and three-year securities. Proceeds for the state budget amounted to almost UAH7.6bn. The MoF decreased interest rates for 12-month paper only.
EQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian...
Issuer: CureVac / Key word(s): Study CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK 24.04.2024 / 13:03 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will as...
EQS-News: CureVac gibt Start einer kombinierten Phase-1/2-Studie zur V...
Emittent / Herausgeber: CureVac / Schlagwort(e): Studie CureVac gibt Start einer kombinierten Phase-1/2-Studie zur Vogelgrippe (H5N1) bekannt; Entwicklung in Zusammenarbeit mit GSK 24.04.2024 / 13:03 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac gibt Start einer kombinierten Phase-1/2-Studie zur Vogelgrippe (H5N1) bekannt; Entwicklung in Zusammenarbeit mit GSK Phase-1-Teil einer kombinierten Phase-1/2-Studie gestartet, im Rahmen der Pandemievorsorge gegen das hoch pathogene Vogelgrippevirus (H5N1), das mögliche zukünftige...
Travere Therapeutics and CSL Vifor Announce European Commission Approv...
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparse...
Form 8.3 - Apex Fundrock Limited : Form 8.3 - Tyman PLC
Apex Fundrock Limited (MISL) Form 8.3 - Apex Fundrock Limited : Form 8.3 - Tyman PLC 24-Apr-2024 / 11:56 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trust...
EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business O...
Issuer: CureVac / Key word(s): Personnel CureVac Appoints Thaminda Ramanayake as New Chief Business Officer 24.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Appoints Thaminda Ramanayake as New Chief Business Officer Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, Germany/BOSTON, USA – A...
EQS-News: CureVac ernennt Thaminda Ramanayake zum neuen Chief Business...
Emittent / Herausgeber: CureVac / Schlagwort(e): Personalie CureVac ernennt Thaminda Ramanayake zum neuen Chief Business Officer 24.04.2024 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac ernennt Thaminda Ramanayake zum neuen Chief Business Officer Herr Ramanayake verfügt über mehr als 15 Jahre Erfahrung in der Entwicklung von Biopharma-Unternehmen und in Geschäftsabschlüssen Er erzielte große Erfolge beim Abschluss klinischer Kooperationen, M&A, Einlizensierungen und strategischen Finanzierungsinitiativen in v...
R.E.A. Holdings plc: Notification of Major Holdings
R.E.A. Holdings plc (RE.) R.E.A. Holdings plc: Notification of Major Holdings 24-Apr-2024 / 12:00 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB0002349065 Issuer Name R.E.A. HOLDINGS PLC UK or Non-UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3. Details of person subject to the notification obligation Name Arbuthnot Latham (Nominees) Limited City of registered office (if applicable) London Country of registered office (if applicable) Un...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cance...
Rogers Communications Reports First Quarter 2024 Results
Rogers Communications Reports First Quarter 2024 Results Reports nine straight quarters of industry-leading growthReaffirms industry-leading 2024 financial guidance More Canadians continue to choose Rogers over any other carrier 124,000 postpaid mobile phone and retail Internet net addsPostpaid mobile phone net adds of 98,000, up 3,000Retail Internet net adds of 26,000, up 12,000 Delivers industry-leading growth in Cable and Wireless Total service revenue up 31%; adjusted EBITDA up 34%Wireless service revenue and adjusted EBITDA up 9% Wireless blended ARPU up...
Shenandoah Telecommunications Company to Hold its First Quarter 2024 E...
Shenandoah Telecommunications Company to Hold its First Quarter 2024 Earnings Call at 8:30 a.m. on Friday, May 3, 2024 EDINBURG, Va., April 24, 2024 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (Shentel) (NASDAQ:SHEN) will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024, and will host a conference call and simultaneous webcast on the same day at 8:30 a.m. Eastern Time to discuss Shentel’s financial results and business highlights. Date: May 3, 2024Time: 8:30 AM ET Listen via Internet: For Analysts, please register to dial-in...
Smart Share Global Limited Files Its Annual Report on Form 20-F
Smart Share Global Limited Files Its Annual Report on Form 20-F SHANGHAI, April 24, 2024 (GLOBE NEWSWIRE) -- Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the United States Securities and Exchange Commission (the “SEC”) on April 24, 2024. The annual report can be accessed on the Company’s investor relations website at / and on the SEC’s website at The Company will provide a hard copy...
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beck...
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression. from the recently completed monotherapy Part 1 of the study were shared in March 2024, and showed that a single dose of BPL-003 was safe and well-tolerated, with a rapid and durable antidepressant effect lasting up to 12-weeks post-dose. Part 2 of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.